Jubilant Pharmova (JUBLPHARMA) | Stock Overview & Key Data
Jubilant Pharmova Performance Comparison
Stock Range
Today's Range
Low: ₹1,088.70
High: ₹1,113.40
on August 8, 2025
52 Week Range
Low: ₹802.00
High: ₹1,309.90
on April 7, 2025
on November 7, 2024
All-Time High: ₹1,309.90 on November 4, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR179.0B
EPS
28.96
P/E Ratio (TTM)
38.96
Forward P/E
23.15
P/B Ratio
2.85
PEG Ratio
0.04
Div. Yield
0.85%
ROE
13.45%
Beta
0.700
Debt to Equity
43.78
Financial Highlights
Profitability
Gross Margin
67.10%
Operating Margin
10.08%
Profit Margin
6.22%
Returns and Earnings
Return on Assets (TTM)
6.58%
Return on Equity (TTM)
13.45%
EBITDA
INR12.7B
Net Income (TTM)
INR4.6B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR467.40
Quarterly Revenue Growth (YoY)
9.80%
Quarterly Earnings Growth (YoY)
-78.70%
Dividend Information
Last 12-Month Dividend
₹10.00
Current Dividend Yield
0.85%
3-Year Average Dividend Yield
0.89%
3-Year Average Annual Dividend
₹6.67
3-Year Total Dividends
₹20.00
Ex-Dividend Date
July 25, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Jubilant Pharmova JUBLPHARMA | 179.04B Mid-cap | -7.60% | -8.08% | 25.13% | 10.32% | 2.17% | 28.28% | 215.35% | 82.21% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | -6.35% | -4.85% | -10.27% | -8.65% | -15.43% | -8.07% | 74.63% | 200.22% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | -7.04% | -10.99% | -0.27% | -0.15% | 0.96% | 26.95% | 64.55% | 98.44% |
| Alembic APLLTD | 184.02B Mid-cap | -2.82% | -5.18% | 5.97% | 7.18% | -9.40% | -15.92% | 45.65% | -8.45% |
| Natco Pharma NATCOPHARM | 165.30B Mid-cap | -0.88% | -2.94% | 16.21% | -28.38% | -32.37% | -36.28% | 41.79% | 10.64% |
| Neuland Laboratories NEULANDLAB | 164.59B Mid-cap | -3.39% | 8.87% | 6.08% | -9.94% | -10.24% | 11.20% | 1,073.41% | 1,495.56% |
Ownership & Short Interest
Insider Ownership
60.70%
Institutional Ownership
19.58%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
480K
Average 90-Day Volume
367K
Jubilant Pharmova Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Jubilant Pharmova would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is JUBLPHARMA's 52-week high and low?
- In the last 52 weeks, Jubilant Pharmova reached a high of ₹1,309.90 (on November 7, 2024) and a low of ₹802.00 (on April 7, 2025).
- What is the market cap and P/E ratio for JUBLPHARMA?
- Curious about Jubilant Pharmova's size and valuation? Its market capitalization stands at 179.04B. When it comes to valuation, the P/E ratio (trailing twelve months) is 38.96, and the forward P/E (looking ahead) is 23.15.
- Does JUBLPHARMA pay dividends? If so, what's the yield?
- Yes, Jubilant Pharmova is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.85%, and the company has paid an average of ₹6.67 per share annually over the past 3 years.
- Who are Jubilant Pharmova's main competitors or similar companies to consider before investing?
When looking at Jubilant Pharmova, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -8.07% 74.63% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 26.95% 64.55% Alembic
APLLTD184.02B Healthcare Drug Manufacturers - Specialty & Generic -15.92% 45.65% Natco Pharma
NATCOPHARM165.30B Healthcare Drug Manufacturers - Specialty & Generic -36.28% 41.79% Neuland Laboratories
NEULANDLAB164.59B Healthcare Drug Manufacturers - Specialty & Generic 11.20% 1,073.41% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Jubilant Pharmova Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Jubilant Pharmova's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 13.45%, the Debt to Equity ratio from the most recent quarter is 43.78, and its Gross Profit Margin stands at 67.10%.
- What is the recent revenue and earnings growth for JUBLPHARMA?
- Looking at Jubilant Pharmova's growth, its revenue over the trailing twelve months (TTM) was INR74B. Compared to the same quarter last year (YoY), quarterly revenue grew by 9.80%, and quarterly earnings saw a YoY growth of -78.70%.
- How much of JUBLPHARMA stock is held by insiders and institutions?
- Wondering who owns Jubilant Pharmova stock? Company insiders (like executives and directors) hold about 60.70% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 19.58%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.